SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

$SWEAT is the beating heart of the Movement Economy—a groundbreaking token that transforms physical activity into real-world value. Minted through movement, $SWEAT rewards your steps with a crypto asset that you can earn, trade, or grow. The team states that their app has increased their users’ physical activity by an average of 20%, creating a healthier society and reducing burdens on global healthcare systems. With over 20 million holders, SWEAT is eliminating barriers and making Web3 accessible to everyone, one step at a time.

Sweat Economy

Sweat Economy is capturing significant community attention as users debate its long-term potential and wait for a sustained recovery. While some investors express frustration over price action, many remain optimistic, comparing the token's prospects to a phoenix rising from the ashes.

Samsara, Inc. develops internet connected sensor systems. It combines plug-and-play sensors, wireless connectivity, and cloud-hosted software integrated for deployment. The company was founded by John Bicket and Sanjit Biswas in 2015 and is headquartered in San Francisco, CA.

Samsara Inc - Ordinary Shares - Class A

Samsara Inc

Samsara Inc. (IOT) is currently drawing significant investor interest as the market positions itself for the upcoming quarterly earnings report. The community is actively debating the stock's growth potential and valuation, with many traders closely watching technical resistance levels as they balance excitement over the company's AI-driven industrial platform against broader software sector volatility.

Pi Network is a social cryptocurrency and developer platform designed to make digital currency mining accessible to everyday people through mobile devices. The project aims to build a widely distributed currency that facilitates transactions for real-world goods and services rather than purely speculative trading. Its main value proposition is a mobile-first mining system that allows users to earn rewards on their phones without requiring specialized hardware, draining battery life, or using excessive data.  The network operates on the Stellar Consensus Protocol and a Federated Byzantine Agreement, which allows computers to reach agreement by trusting specific groups of other peers. Security is maintained through a global trust graph built from individual user groups called security circles where members vouch for each other. Users participate in four primary roles as pioneers, contributors, ambassadors, or nodes to ensure the network remains decentralized. This meritocratic distribution model rewards consistent engagement and network growth rather than financial wealth or technical power.  Founded by Dr. Nicolas Kokkalis and Dr. Chengdiao Fan, both of whom hold doctoral degrees from Stanford University, the project is managed by Social Chain Inc. The ecosystem includes a native wallet, a dedicated browser, and a platform for decentralized applications where the PI token is used for peer-to-peer exchange and transaction fees. Additionally, tokens can be used for purchasing goods in an internal marketplace, staking in a launchpad, or voluntary lockups that support market stability while boosting personal mining rates. The project has focused on organic community growth and does not list any external institutional investors in its documentation.

Pi Network

Pi Network continues to trigger heated debate as users remain divided over long-standing concerns regarding unverified balance releases, the project's extended development timeline, and its monetization through in-app advertising. While skeptics label the project a scam, proponents remain focused on its long-term potential, frequently citing anticipated infrastructure upgrades and the promise of a broader, utility-driven ecosystem.

Fox Corp. engages in providing television production and broadcasting services. It also provides news under the brands FOX News Media, FOX Sports, FOX Entertainment and FOX Television Stations, and Tubi Media Group. It operates through the following segments: Cable Network Programming, Television, and Other and Corporate. The Cable Network Programming segment refers to the production and licensing of news and sports content distributed primarily through traditional cable television systems, direct broadcast satellite operators, and telecommunication companies and online multi-channel video programming distributors. The Television segment focuses on the acquisition, marketing, and distribution of broadcast network programming. The Other and Corporate segment relates to the FOX Studio Lot, Credible Labs Inc, corporate overhead costs, and intracompany eliminations. The company was founded by Keith Rupert Murdoch on May 3, 2018, and is headquartered in New York, NY.

Fox Corporation - Ordinary Shares - Class A

Fox Corporation

Fox Corporation is currently drawing attention following strong quarterly earnings and continued market interest in its strategy of leveraging live sports and news content to drive growth. The community remains focused on the company's competitive position within the evolving streaming landscape and its ability to maintain audience engagement across its flagship platforms.

Funko, Inc. engages in designing, sourcing, and distributing licensed pop culture products. Its product lines include media and entertainment content, which refer to movies, TV shows, video games, music, and sports. It operates through the United States, Europe, and Other International geographic segments. The company was founded in 1998 and is headquartered in Everett, WA.

Funko Inc - Ordinary Shares - Class A

Funko Inc. is seeing heightened market attention as investors speculate on potential buyout interest and a broader turnaround strategy, supported by bullish sentiment around recent product launches and debt reduction efforts. The community is actively discussing the stock's potential for a short squeeze, while carefully monitoring management's ability to maintain margins and navigate broader economic pressures.

KAIO provides institutional-grade real-world asset (RWA) tokenization infrastructure that seamlessly connects traditional investment funds with digital capital markets. Through its purpose-built protocol, KAIO enables leading global asset managers to issue and distribute regulated tokenized funds across multiple high-performance blockchain networks — including Ethereum, Sei, Hedera, Solana, Aptos, and others — significantly expanding global access to institutional-quality real-world asset strategies for qualified investors.   By tokenizing feeder structures and shares in flagship funds, KAIO brings onchain access to proven strategies such as the BlackRock ICS US Dollar Liquidity Fund (one of the world’s largest institutional money market funds), the Brevan Howard Master Fund, Hamilton Lane’s Senior Credit Opportunities Fund (SCOPE) via the HL SCOPE Access Fund, and Laser Digital’s Laser Carry Fund (LCF), among others. These tokenized vehicles deliver secure, compliant exposure to money market, macro, private credit, and alternative strategies while unlocking new levels of programmability, composability, and 24/7 liquidity in DeFi environments.

KAIO

KAIO is trending as market participants speculate on a potential price reversal driven by heavy accumulation and its positioning within the real-world assets sector. While some traders are bullish on a breakout and increased accessibility to assets, others remain cautious due to recent downward volatility and inconsistent performance since launch.

Hyperliquid is a layer one (L1) blockchain best known for perpetual futures and spot trading. Beyond its flagship DEX trading platform, the ecosystem supports borrowing, lending, real world assets (RWAs), and a full-fledged Ethereum Virtual Machine (EVM), making it a leading force in decentralized finance (defi).   Just as electronic trading dramatically improved markets in the 2000s, Hyperliquid offers an opportunity for a massive technical upgrade of the existing financial system through a transparent, efficient, and resilient blockchain. HYPE is the native token of the Hyperliquid blockchain, with a maximum supply of 1 billion.

Hype

HYPE is experiencing intense buying pressure and market interest, driven by its status as a core infrastructure for decentralized perpetual trading and its expanding utility for tokenized assets. The community is actively discussing the platform's sustained growth, institutional discovery, and the significant impact of its unique revenue-sharing and buyback mechanisms as it continues to record new highs.

adidas AG engages in the design, distribution, and marketing of athletic and sporting lifestyle products. It operates through the following geographical segments: EMEA, North America, Greater China, Asia-Pacific, Latin America, and Other Businesses. The Other Businesses segment includes the activities of the Y-3 label and other subordinated businesses. The company was founded by Adolf Dassler in 1920 and is headquartered in Herzogenaurach, Germany.

Adidas AG - ADR - Level I

Adidas

Adidas is trending as investors monitor the company's strategic turnaround and its ability to maintain brand relevance in a competitive sportswear landscape, while the community remains divided over the long-term impact of its high-profile brand shifts and recent partnership transitions. Discussions are heavily focused on comparing Adidas's performance and valuation against key rivals like Nike, with sentiment split between those seeing a prime buying opportunity in a recovering brand and others concerned about broader economic headwinds affecting the apparel sector.

Dyne Therapeutics, Inc. is a clinical-stage company, which engages in developing innovative life-transforming therapies for genetically driven muscle diseases. It develops a broad portfolio of therapeutics for muscle diseases, including lead programs in myotonic dystrophy type 1, Duchenne muscular dystrophy, and facioscapulohumeral muscular dystrophy. The company was founded by Jason P. Rhodes and Romesh R. Subramanian on December 1, 2017 and is headquartered in Waltham, MA.

Dyne Therapeutics Inc

Dyne Therapeutics is trending as investors react to positive clinical data from its ACHIEVE and DELIVER trials, which demonstrate the potential efficacy of its proprietary FORCE platform in treating rare neuromuscular diseases. The community is actively debating the stock's valuation, potential acquisition interest, and the impact of recent clinical milestones on its long-term competitive positioning within the biotech sector.

Sanofi engages in the research, production, and distribution of pharmaceutical products. It operates through the Biopharma segment, which comprises commercial operations and research, development and production activities relating to the specialty care, general medicines and vaccines franchises plus support and corporate functions, for all geographical territories. The company was founded in 1973 and is headquartered in Paris, France.

Sanofi - ADR

Sanofi-Aventis

Sanofi is attracting significant investor attention as market participants speculate on potential M&A activity involving the company's vaccine and metabolic pipelines. The community is actively discussing rumors of strategic buyouts, Sanofi's partnership with Novavax, and the performance of its key growth franchises like Dupixent.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Why Is Biogen (BIIB) Up 3.8% Since Last Earnings Report?

Biogen (BIIB) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Should You Buy, Sell or Hold BIIB Stock After it Rises Almost 12% YTD?

Biogen climbs 11.5% YTD as new drugs, pipeline progress and M&A activity fuel confidence in Biogen???s multiyear turnaround.

Stoke Therapeutics to Present at Upcoming Investor Conferences in June

Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the bodys potential with RNA medicine and has a lead investigational medicine, zorevunersen, in development as a first-in-class potential disease-modifying treatment for Dravet...

Denali Stock Dips as Biogen-Partnered Parkinson's Disease Study Fails 

DNLI sinks after BIIB122 failed a mid-stage Parkinson's study, prompting Denali and Biogen to halt development in idiopathic cases.

Biogen Inc. (BIIB) Securities Fraud Investigation - Levi & Korsinsky

Biogen Inc. (BIIB) Securities Fraud Investigation - Levi & Korsinsky Biogen Inc. (BIIB) Securities Fraud Investigation - Levi & Korsinsky PR Newswire NEW YORK, May 22, 2026 Biogen shares dropped approximately 6.4% in a single session after Phase 2 CELIA trial data for diranersen missed its primary...

BIIB, DNLI Stocks Edge Lower After Hours: Parkinson’s Drug Misses Key Goals In Trial

Equity

The study did not show that the drug slowed the worsening of motor and daily-living symptoms compared with placebo, the company said. 


INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Biogen Inc. - BIIB

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Biogen Inc. - BIIB INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Biogen Inc. - BIIB PR Newswire NEW YORK, May 21, 2026 NEW YORK, May 21, 2026 /PRNewswire/ -- Pomerantz LLP is...

Is it a Good Idea to Invest in Stoke Therapeutics Stock Now?

STOK rides high as zorevunersen advances in late-stage Dravet syndrome studies and heads toward FDA filing plans.

BIIB Investor Alert: Levi & Korsinsky Investigates Biogen Inc. (BIIB) for Potential Securities Fraud

Biogen Inc. (NASDAQ: BIIB) shareholders lost approximately 6.4% of their investment value on May 14, 2026, when the company disclosed that its Phase 2 "CELIA" trial for Alzheimer's candidate diranersen (BIIB080) failed to meet its primary dose-response endpoint. Investors who lost money on BIIB are...

Immunic appoints Biogen, Cubist veteran Mike Bonney as board chair ahead of key MS trial readout

Immunic appoints Biogen, Cubist veteran Mike Bonney as board chair ahead of key MS trial readout...

Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. Its products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for the treatment of MS, SPINRAZA for the treatment of SMA, ADUHELM for the treatment of Alzheimer's disease, and FUMADERM for the treatment of severe plaque psoriasis. The company was founded by Charles Weissmann, Heinz Schaller, Kenneth Murray, Walter Gilbert, and Phillip Allen Sharp in 1978 and is headquartered in Cambridge, MA.

Fiscal Period	Estimated	Reported	Surprise	Result
Q2 '26	$3.18	--	--	N/A
Q1 '26	$3.08	$3.57	15.77%	BEAT
Q4 '25	$1.63	$1.99	22.45%	BEAT
Q3 '25	$3.88	$4.81	23.89%	BEAT
Q2 '25	$3.90	$5.47	40.38%	BEAT

BIIB
Biogen Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Upcoming Earnings: Q2 '26

Historical Earnings

Compact View

Latest BIIB News

BIIBBiogen Inc